Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

Inclusion Criteria: * Male or female outpatients between 18 and 70 years old inclusive; * symptoms of social anxiety disorders (generalized type) present for at least 1 year prior to Selection Visit; * had a score of \>=60 on the LSAS at the Selection Visit and at the Randomization Visit. Additionally, the clinician's gloal impression of change score must have been \>= 2 at the Randomization Visit; * had a telephone where they could be directly contacted. Exclusion Criteria: * History of autism or Asperger's Disease; * had another primary axis I disorder or fulfilled diagnostic and statistical manual of mental disorders-4th edition (DSM-IV) criteria in the 6 months prior to Screening; * major depression as measured by a Hamilton Depression Rating Scale (HAM-D-17 items) total score of \> 17 and/or a suicide subscale score on the HAM-D-17 items of \> 2 at the Selection or Randomization Visit; * history of electroconvulsive therapy within the prior 3 months; * history of psychotherapy which was not stable and ongoing for at least 6 months prior to Visit 1; * clinical history of significantly impaired renal function with an estimated creatinine clearance below 80 mL/min; * clinically significant medical condition; * history of any clinically significant allergic condition or allergy to LEV or pyrrolidone derivatives; * neutrophil count of less than 1800/µL.